$2.46 Billion is the total value of Cormorant Asset Management, LP's 88 reported holdings in Q3 2021. The portfolio turnover from Q2 2021 to Q3 2021 was 43.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| TPTX | Sell | TURNING POINT THERAPEUTICS I | $188,814,000 | -20.3% | 2,842,297 | -6.4% | 7.67% | -4.7% |
| AVIR | Sell | ATEA PHARMACEUTICALS INC | $172,802,000 | +25.5% | 4,928,756 | -23.1% | 7.02% | +50.1% |
| FMTX | Sell | FORMA THERAPEUTICS HLDGS INC | $109,468,000 | -6.9% | 4,720,495 | -0.0% | 4.45% | +11.4% |
| RVMD | Sell | REVOLUTION MEDICINES INC | $86,511,000 | -18.3% | 3,144,700 | -5.8% | 3.52% | -2.3% |
| BBIO | Sell | BRIDGEBIO PHARMA INC | $82,909,000 | -27.7% | 1,768,909 | -6.0% | 3.37% | -13.5% |
| DSGN | Sell | DESIGN THERAPEUTICS INC | $78,810,000 | -25.6% | 5,364,850 | -0.9% | 3.20% | -11.1% |
| GLUE | Sell | MONTE ROSA THERAPEUTICS INC | $67,957,000 | -2.3% | 3,102,199 | -2.9% | 2.76% | +16.8% |
| BCAB | Sell | BIOATLA INC | $53,450,000 | -35.4% | 1,815,546 | -7.0% | 2.17% | -22.7% |
| RNA | Sell | AVIDITY BIOSCIENCES INC | $53,253,000 | -3.3% | 2,162,115 | -3.0% | 2.16% | +15.7% |
| RAIN | Sell | RAIN THERAPEUTICS INC | $34,807,000 | -12.4% | 2,326,660 | -11.4% | 1.41% | +4.7% |
| TARS | Sell | TARSUS PHARMACEUTICALS INC | $31,136,000 | -29.0% | 1,444,831 | -4.6% | 1.26% | -15.2% |
| ZYME | Sell | ZYMEWORKS INC | $27,588,000 | -39.8% | 950,000 | -28.1% | 1.12% | -28.0% |
| ACRS | Sell | ACLARIS THERAPEUTICS INC | $27,000,000 | -23.1% | 1,500,000 | -25.0% | 1.10% | -8.0% |
| MRTX | Sell | MIRATI THERAPEUTICS INC | $21,229,000 | -24.9% | 120,000 | -31.4% | 0.86% | -10.1% |
| LBPH | Sell | LONGBOARD PHARMACEUTICALS IN | $20,155,000 | -3.4% | 2,273,221 | -2.1% | 0.82% | +15.5% |
| BPMC | Sell | BLUEPRINT MEDICINES CORP | $15,422,000 | -26.2% | 150,000 | -36.9% | 0.63% | -11.7% |
| YMAB | Sell | Y-MABS THERAPEUTICS INC | $14,270,000 | -47.2% | 500,000 | -37.5% | 0.58% | -36.9% |
| OMER | Sell | OMEROS CORP | $13,100,000 | -26.4% | 950,000 | -20.8% | 0.53% | -12.1% |
| PHVS | Sell | PHARVARIS N V | $12,229,000 | -10.3% | 689,731 | -7.4% | 0.50% | +7.3% |
| CNTB | Sell | CONNECT BIOPHARMA HLDGS LTDads | $11,950,000 | -5.9% | 500,000 | -23.1% | 0.49% | +12.8% |
| ALGS | Sell | ALIGOS THERAPEUTICS INC | $10,348,000 | -43.9% | 667,167 | -26.3% | 0.42% | -33.0% |
| RETA | Sell | REATA PHARMACEUTICALS INCcl a | $10,061,000 | -57.7% | 100,000 | -40.5% | 0.41% | -49.4% |
| Sell | DERMTECH INC | $9,633,000 | -48.5% | 300,000 | -33.3% | 0.39% | -38.4% | |
| ELDN | Sell | ELEDON PHARMACEUTICALS INC | $8,065,000 | -28.0% | 1,305,095 | -7.8% | 0.33% | -13.7% |
| MYOV | Sell | MYOVANT SCIENCES LTD | $6,732,000 | -45.5% | 300,000 | -44.7% | 0.27% | -34.8% |
| Sell | APTOSE BIOSCIENCES INC | $6,540,000 | -48.3% | 3,000,000 | -21.2% | 0.27% | -38.0% | |
| MORF | Sell | MORPHIC HLDG INC | $5,664,000 | -48.0% | 100,000 | -47.3% | 0.23% | -37.8% |
| VRDN | Sell | VIRIDIAN THERAPEUTICS INC | $5,635,000 | -10.2% | 342,562 | -0.1% | 0.23% | +7.5% |
| MRUS | Sell | MERUS N V | $5,500,000 | -8.4% | 250,000 | -12.3% | 0.22% | +9.3% |
| GLTO | Sell | GALECTO INC | $4,131,000 | -53.4% | 1,150,730 | -34.4% | 0.17% | -44.2% |
| SRNE | Sell | SORRENTO THERAPEUTICS INC | $3,052,000 | -37.0% | 400,000 | -20.0% | 0.12% | -24.8% |
| QTNT | Sell | QUOTIENT LTD | $2,340,000 | -46.6% | 1,000,000 | -16.9% | 0.10% | -36.2% |
| NERV | Sell | MINERVA NEUROSCIENCES INC | $167,000 | -70.7% | 95,744 | -61.0% | 0.01% | -63.2% |
| OTLKW | Sell | OUTLOOK THERAPEUTICS INC*w exp 02/18/202 | $54,000 | -58.5% | 270,698 | -35.0% | 0.00% | -50.0% |
| NUVBWS | Exit | NUVATION BIO INC*w exp 07/07/202 | $0 | – | -83,332 | -100.0% | -0.01% | – |
| CEREW | Exit | CEREVEL THERAPEUTICS HLDNG I*w exp 06/09/202 | $0 | – | -19,316 | -100.0% | -0.01% | – |
| CRDF | Exit | CARDIFF ONCOLOGY INC | $0 | – | -95,720 | -100.0% | -0.02% | – |
| SWTX | Exit | SPRINGWORKS THERAPEUTICS INC | $0 | – | -15,000 | -100.0% | -0.04% | – |
| TCDA | Exit | TRICIDA INC | $0 | – | -427,975 | -100.0% | -0.06% | – |
| EIGR | Exit | EIGER BIOPHARMACEUTICALS INC | $0 | – | -284,988 | -100.0% | -0.08% | – |
| HSAQ | Exit | HEALTH SCIENCES ACQ CORP 2 | $0 | – | -240,000 | -100.0% | -0.08% | – |
| GTH | Exit | GENETRON HLDGS LTDads | $0 | – | -132,867 | -100.0% | -0.09% | – |
| FVAM | Exit | 5 01 ACQUISITION CORP | $0 | – | -400,000 | -100.0% | -0.14% | – |
| TBPH | Exit | THERAVANCE BIOPHARMA INC | $0 | – | -300,000 | -100.0% | -0.15% | – |
| AVEO | Exit | AVEO PHARMACEUTICALS INC | $0 | – | -893,500 | -100.0% | -0.20% | – |
| INSM | Exit | INSMED INC | $0 | – | -250,000 | -100.0% | -0.24% | – |
| SBTX | Exit | SILVERBACK THERAPEUTICS INC | $0 | – | -239,099 | -100.0% | -0.25% | – |
| Exit | CATABASIS PHARMACEUTICALS IN | $0 | – | -3,550,000 | -100.0% | -0.25% | – | |
| BCTG | Exit | BCTG ACQUISITION CORP | $0 | – | -800,000 | -100.0% | -0.31% | – |
| ZLAB | Exit | ZAI LAB LTDadr | $0 | – | -53,455 | -100.0% | -0.32% | – |
| HGEN | Exit | HUMANIGEN INC | $0 | – | -600,000 | -100.0% | -0.35% | – |
| RPTX | Exit | REPARE THERAPEUTICS INC | $0 | – | -363,766 | -100.0% | -0.38% | – |
| CCCC | Exit | C4 THERAPEUTICS INC | $0 | – | -354,495 | -100.0% | -0.46% | – |
| OMER | Exit | OMEROS CORPcall | $0 | – | -1,000,000 | -100.0% | -0.50% | – |
| MASS | Exit | 908 DEVICES INC | $0 | – | -545,320 | -100.0% | -0.72% | – |
| XLRN | Exit | ACCELERON PHARMA INC | $0 | – | -175,000 | -100.0% | -0.75% | – |
| TWST | Exit | TWIST BIOSCIENCE CORP | $0 | – | -185,000 | -100.0% | -0.84% | – |
| ARKK | Exit | ARK ETF TRput | $0 | – | -500,000 | -100.0% | -2.22% | – |
| ARKG | Exit | ARK ETF TRput | $0 | – | -750,000 | -100.0% | -2.36% | – |
| IWM | Exit | ISHARES TRput | $0 | – | -1,000,000 | -100.0% | -7.79% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-11-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| QUOTIENT LTD | 30 | Q3 2021 | 4.3% |
| ASCENDIS PHARMA A/S | 30 | Q4 2022 | 4.8% |
| MINERVA NEUROSCIENCES INC | 29 | Q3 2021 | 4.4% |
| ACCELERON PHARMA INC | 28 | Q2 2021 | 3.4% |
| OMEROS CORP | 27 | Q3 2021 | 6.5% |
| MIRATI THERAPEUTICS INC | 25 | Q4 2022 | 7.6% |
| BLUEPRINT MEDICINES CORP | 25 | Q3 2021 | 3.6% |
| APELLIS PHARMACEUTICALS INC | 24 | Q3 2023 | 8.6% |
| NEUROCRINE BIOSCIENCES INC | 24 | Q1 2020 | 4.6% |
| ROCKET PHARMACEUTICALS, INC | 23 | Q3 2023 | 2.4% |
View Cormorant Asset Management, LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Ambrx Biopharma Inc. | March 13, 2023 | 42,771,365 | - |
| Altimmune, Inc. | February 14, 2023 | 2,600,000 | - |
| Arcellx, Inc. | February 14, 2023 | 2,075,000 | - |
| BioAtla, Inc. | February 14, 2023 | 2,499,250 | - |
| Eledon Pharmaceuticals, Inc. | February 14, 2023 | 1,391,663 | - |
| GreenLight Biosciences Holdings, PBC | February 14, 2023 | 4,751,020 | - |
| Prometheus Biosciences, Inc. | February 14, 2023 | 700,000 | - |
| Tango Therapeutics, Inc. | February 14, 2023 | 1,000,000 | - |
| VectivBio Holding AG | February 14, 2023 | 1,515,087 | - |
| Viridian Therapeutics, Inc.\DE | February 14, 2023 | 1,100,000 | - |
View Cormorant Asset Management, LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-04-29 |
| 4 | 2024-04-22 |
| SC 13G/A | 2024-04-15 |
| 4 | 2024-04-03 |
| SC 13G | 2024-03-21 |
| 4 | 2024-03-18 |
| SC 13G/A | 2024-03-18 |
| 4 | 2024-03-11 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View Cormorant Asset Management, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.